Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia

[1] Grupp SA(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-1518

[2] Kalos M(2012)B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 12-528

[3] Barrett D(2013)Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation Blood 122 25-295

[4] Kochenderfer JN(2014)Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 224ra25-549

[5] Dudley ME(2013)CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 177ra38-3020

[6] Feldman SA(2012)CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results Blood 119 17-1517

[7] Kochenderfer JN(2015)T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 385 517-679

[8] Dudley ME(2016)Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL Blood 127 24-422

[9] Carpenter RO(2011)T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Leukemia 3 95ra73-476

[10] Davila ML(2017)Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma Mol Ther 25 285-undefined

[1] Grupp SA(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-1518

[2] Kalos M(2012)B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 12-528

[3] Barrett D(2013)Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation Blood 122 25-295

[4] Kochenderfer JN(2014)Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 224ra25-549

[5] Dudley ME(2013)CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 177ra38-3020

[6] Feldman SA(2012)CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results Blood 119 17-1517

[7] Kochenderfer JN(2015)T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 385 517-679

[8] Dudley ME(2016)Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL Blood 127 24-422

[9] Carpenter RO(2011)T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Leukemia 3 95ra73-476

[10] Davila ML(2017)Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma Mol Ther 25 285-undefined